SCHEMBL6659345

SCHEMBL6659345

CCOC(=O)C(=O)Nc1cc(Cl)c(Oc2ccc(O)c(C(=O)N[C@H](C)C3CCCCC3)c2)c(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
THRB P10828 12/20 0.50
THRA P10827 11/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6659937 1.00 THRB (0.50) THRBTHRA
SCHEMBL6659824 0.96 THRB (0.53) THRBTHRA
SCHEMBL6665549 0.96 THRB (0.53) THRBTHRA
SCHEMBL7792555 0.96 THRB (0.53) THRBTHRA
SCHEMBL6663010 0.92 THRA (0.52) THRBTHRA
SCHEMBL6663366 0.90 THRA (0.58) THRBTHRA
SCHEMBL6658953 0.88 THRB (0.53) THRBTHRA
SCHEMBL6660589 0.87 THRB (0.54) THRBTHRA
SCHEMBL7796615 0.86 THRA (0.52) THRBTHRA
SCHEMBL6662726 0.86 THRA (0.52) THRBTHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030114521-A1 Oxamic acids and derivatives as thyroid receptor ligands CHIANG YUAN-CHING PHOEBE (US) 2003-06-19 US claimed
US-6545018-B2 Treating obesity, hyperlipidemia, glaucoma, arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis PFIZER INC. 2003-04-08 US claimed
US-20020049226-A1 Oxamic acids and derivatives as thyroid receptor ligands CHIANG YUAN-CHING PHOEBE (US) 2002-04-25 US claimed
EP-1157001-B1 OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS PFIZER PROD INC (US) 2004-08-04 EP disclosed
US-20030114521-A1 Oxamic acids and derivatives as thyroid receptor ligands CHIANG YUAN-CHING PHOEBE (US) 2003-06-19 US disclosed
US-6545018-B2 Treating obesity, hyperlipidemia, glaucoma, arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis PFIZER INC. 2003-04-08 US disclosed
US-20020049226-A1 Oxamic acids and derivatives as thyroid receptor ligands CHIANG YUAN-CHING PHOEBE (US) 2002-04-25 US disclosed
US-6326398-B1 Oxamic acids and derivatives as thyroid receptor ligands PFIZER INC. 2001-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114521-A1 Oxamic acids and derivatives as thyroid receptor ligands OXER1, THRA, TSHR THRB 4/4885THRA 2/4885
US-20020049226-A1 Oxamic acids and derivatives as thyroid receptor ligands OXER1, THRA, OXGR1 THRB 4/4885THRA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.